INBIOGEN Co., Ltd. (KRX:101140)
South Korea · Delayed Price · Currency is KRW 8,890.00
+90.00 (1.02%)
At close: Apr 24, 2026
INBIOGEN Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,419 | 16,122 | 11,344 | -117,218 | 94,125 |
Depreciation & Amortization | 363.49 | 1,057 | 1,224 | 1,438 | 1,117 |
Loss (Gain) From Sale of Assets | -61.39 | 168.14 | 65.35 | - | 138.43 |
Asset Writedown & Restructuring Costs | 1,052 | 992.37 | - | - | - |
Loss (Gain) From Sale of Investments | -30.65 | 1.04 | -39,032 | 178,976 | -123,863 |
Loss (Gain) on Equity Investments | -2,979 | -21,538 | 32,458 | -42,777 | 5,062 |
Provision & Write-off of Bad Debts | 41.93 | 146.46 | 129.11 | -73.23 | 361.64 |
Other Operating Activities | -18.8 | 546.74 | -8,551 | -29,527 | 18,627 |
Change in Accounts Receivable | -1,701 | -115.2 | 2,583 | 1,718 | -2,088 |
Change in Inventory | 81.1 | 66.65 | -605.69 | -835.19 | -450.99 |
Change in Accounts Payable | -422.67 | 218.13 | -233.19 | -412.39 | -60.71 |
Change in Other Net Operating Assets | -461.64 | 2,301 | -432.25 | -2,794 | -37.39 |
Operating Cash Flow | -5,554 | -33.13 | -1,051 | -11,505 | -7,069 |
Capital Expenditures | -42.5 | -84.28 | -25.96 | -130.68 | -2,360 |
Sale of Property, Plant & Equipment | 64.98 | 10.05 | 73.81 | 29.84 | 4.6 |
Sale (Purchase) of Intangibles | - | - | -305 | -200 | -41.15 |
Investment in Securities | - | - | 64.43 | -15,664 | -38,000 |
Other Investing Activities | 444 | 0 | 0 | 0 | - |
Investing Cash Flow | 466.48 | -74.23 | -192.72 | -15,925 | -40,437 |
Long-Term Debt Issued | 500 | - | - | - | 15,000 |
Total Debt Issued | 500 | - | - | - | 15,000 |
Long-Term Debt Repaid | -227.03 | -265.3 | -1,895 | -28,432 | -777.72 |
Total Debt Repaid | -227.03 | -265.3 | -1,895 | -28,432 | -777.72 |
Net Debt Issued (Repaid) | 272.97 | -265.3 | -1,895 | -28,432 | 14,222 |
Issuance of Common Stock | - | - | - | 12,000 | - |
Repurchase of Common Stock | - | - | -62.49 | - | - |
Other Financing Activities | -0 | - | -0 | - | -0 |
Financing Cash Flow | 272.97 | -265.3 | -1,957 | 13,568 | 61,543 |
Miscellaneous Cash Flow Adjustments | 0 | -0 | -0 | - | -0 |
Net Cash Flow | -4,815 | -372.65 | -3,201 | -13,862 | 14,038 |
Free Cash Flow | -5,597 | -117.41 | -1,077 | -11,636 | -9,430 |
Free Cash Flow Margin | -88.88% | -1.67% | -17.25% | -111.67% | -89.97% |
Free Cash Flow Per Share | - | -11.76 | -126.51 | -3209.03 | -3155.62 |
Cash Interest Paid | 73.45 | 0.03 | 10.7 | 142.04 | 220.28 |
Cash Income Tax Paid | -0.39 | -0.26 | -11.3 | 1.41 | -13.53 |
Levered Free Cash Flow | -4,061 | -1,145 | -1,660 | -16,530 | -8,817 |
Unlevered Free Cash Flow | -4,012 | -1,113 | -1,496 | -14,226 | -6,423 |
Change in Working Capital | -2,504 | 2,471 | 1,312 | -2,324 | -2,637 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.